Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Nov 11, 2024 6:53pm
168 Views
Post# 36307408

worth repeating

worth repeating My compliments to notale, for vwery concise recap of ONCs bio, vs anoher company with much less trading at $2.8 billion.
Im repostng this , as far more important than any drivel, other backgound drivel
Thanks for the hard work notable.
.So let's get back to the facts of the matter. CGON has one indication in late stage clinical trials and has a market cap of US$2.7 Billion.

ONCY has 5 indications that are Phase 2/3 / Accelerated Approval ready.

This is particularly threatenting to those others who are supporting other oncolytic virus companies and who post smack on this message board.

These 5 indications with pelareorep are:
(1) HR+/HER2 negative metastatic breast cancer;
(2) Triple Negative Breast Cancer (TNBC);
(3) pancreatic cancer with pelareorep + ICI + n-paclitaxel;
(4) 
pancreatic cancer with pelareorep + ICI + folfirinox, and;
(5) anal (SCCA) cancers. 

Furthermore, ONCY needs to update its shareholders that pelareorep is effective as a single dose in the treatment of Hepatocellular carcinoma cancer (
HCC), as recently demonstrated in an updated paper.


https://stockhouse.com/companies/bullboard?symbol=t.onc&postid=34674668

https://www.medrxiv.org/content/10.1101/2024.09.26.24314049v
<< Previous
Bullboard Posts
Next >>